Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apremilast - Amgen

Next Previous
Drug Profile

Apremilast - Amgen

Alternative Names: AMG-407; CC-10004; CC-1004; OTEZLA

Latest Information Update: 01 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Amgen; Baylor Research Institute; Celgene Corporation
  • Class Acetamides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Isoindoles; Phthalimides; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Behcet's syndrome; Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Behcet's syndrome; Plaque psoriasis; Psoriatic arthritis
  • Phase III Juvenile rheumatoid arthritis; Palmoplantar pustulosis; Psoriasis
  • Phase II Lichen planus
  • Discontinued Ankylosing spondylitis; Asthma; Atopic dermatitis; Bullous pemphigoid; Cancer; COVID 2019 infections; Crohn's disease; Eczema; Hidradenitis suppurativa; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 12 Dec 2025 Amgen completes a phase III long-term extension trial for Plaque psoriasis (In children, In adolescents) in USA, Spain, Italy, Israel, France, Czech Republic, Russia, Canada and Belgium (PO) (NCT04175613)
  • 05 Dec 2025 Amgen completes the phase-III ESSENCE trial for Plaque psoriasis in China (PO) (NCT06122649)
  • 24 Oct 2025 Efficacy data from the phase IV FOREMOST trial in Psoriatic arthritis presented at the ACR Conference 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top